Fig. 2From: Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialKaplan-Meyer analysis evaluating the progression free survival (PFS) and the overall survival (OS) of patients from the MITO16a-MaNGO-OV2i stratified according to EGFR membrane expression by immunohistochemical stainingBack to article page